Aclaris Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-34.6M | $-34.8M | $232.0K | $6.1M |
| FY2017 | $-54.7M | $-55.9M | $1.2M | $14.4M |
| FY2018 | $-100.8M | $-102.2M | $1.4M | $20.1M |
| FY2019 | $-96.4M | $-98.1M | $1.6M | $16.2M |
| FY2020 | $-38.6M | $-39.1M | $453.0K | $11.2M |
| FY2021 | $-52.1M | $-52.4M | $308.0K | $14.1M |
| FY2022 | $-67.6M | $-68.2M | $605.0K | $15.0M |
| FY2023 | $-78.3M | $-79.6M | $1.3M | $20.5M |
| FY2024 | $-20.1M | $-20.2M | $121.0K | $10.9M |
| FY2025 | $-47.1M | $-47.2M | $111.0K | $12.4M |